Merck has paid an uninterrupted dividend since 1935. The pharmaceutical giant funds that payout with a portfolio anchored by Keytruda, the world’s best-selling oncology drug, and a pipeline of vaccines and specialty medicines that generate reliable cash flow. For income investors who want healthcare exposure without the volatility of biotech startups, MRK stock offers a yield backed by one of the most durable revenue streams in the sector.
The setup: Merck’s revenue engine and dividend history
Merck generated approximately $64 billion in revenue in fiscal 2025. Oncology accounted for roughly half of that total, with Keytruda sales exceeding $29 billion. The drug is approved for more than 40 indications across lung cancer, melanoma, head and neck cancer, and other tumor types. Patent exclusivity on Keytruda extends through 2028 in the United States, with additional formulation patents and biosimilar barriers that could stretch revenue protection into the early 2030s.
The pharmaceutical division is not the only contributor. The animal health business generates approximately $6 billion annually with margins that rival the human pharmaceutical segment. Merck also holds a significant position in vaccines through products for HPV, pneumonia, and shingles.
Key numbers for Merck income investors
| Metric | Current Value | Context |
|---|---|---|
| Quarterly Dividend | $0.81 per share | Increased from $0.77 in 2024 |
| Annual Dividend Yield | ~3.1% | Based on recent trading near $104 |
| Payout Ratio | ~50% | From adjusted earnings per share |
| Years of Consecutive Increases | 13 years | Dividend growth resumed post-Vioxx |
| Keytruda Annual Sales | $29+ billion | Largest oncology drug globally |
The 3.1 percent yield places Merck near the top of the large-cap pharmaceutical peer group. Johnson & Johnson yields slightly less. AbbVie yields more but faces the Humira biosimilar cliff. Bristol Myers Squibb carries higher patent expiration risk. Merck sits in the middle, offering yield without the structural overhangs that compress valuations at competitors.
Peer comparison: pharmaceutical dividend yields and coverage
| Company | Ticker | Yield | Annual Dividend | Payout Ratio |
|---|---|---|---|---|
| Merck | MRK | 3.1% | $3.24 | ~50% |
| Johnson & Johnson | JNJ | 2.9% | $4.96 | ~48% |
| AbbVie | ABBV | 3.4% | $6.20 | ~55% |
| Bristol Myers Squibb | BMY | 4.5% | $2.52 | ~65% |
| Pfizer | PFE | 5.8% | $1.68 | ~85% |
Pfizer’s elevated yield reflects post-COVID revenue collapse and pipeline uncertainty, not strength. Bristol Myers Squibb is managing the Eliquis patent cliff. AbbVie is diversifying beyond Humira. Johnson & Johnson is the safest balance sheet in the group. Merck offers a reasonable compromise between yield and fundamental stability.
What to watch for MRK dividend investors
The Keytruda patent cliff is the headline risk. The drug’s composition-of-matter patents expire in 2028. Merck is developing a subcutaneous formulation that could receive new patent protection and delay biosimilar entry. The company is also building an oncology pipeline beyond Keytruda, including antibody-drug conjugates and combination therapies. But no single asset in development matches Keytruda’s revenue scale.
Regulatory risk is another factor. Medicare drug price negotiation under the Inflation Reduction Act applies to selected high-expenditure medicines. Keytruda is a likely target for future negotiation rounds. Price caps could reduce U.S. revenue by 10 to 25 percent for affected products, depending on the negotiated discount.
Per $100,000 income comparison
| Stock | Price (approx) | Shares per $100K | Annual Income |
|---|---|---|---|
| Merck (MRK) | $104 | 962 | $3,116 |
| Johnson & Johnson (JNJ) | $170 | 588 | $2,917 |
| AbbVie (ABBV) | $182 | 549 | $3,405 |
| Pfizer (PFE) | $29 | 3,448 | $5,793 |
Common mistakes income investors make with pharma stocks
Some investors chase the highest yield in the sector without examining why the yield is elevated. Pfizer’s 5.8 percent yield is a distress signal, not a bargain. Others ignore patent cliffs, assuming that a company with a long dividend history will always find a way to maintain the payout. Merck’s own history shows the danger: the dividend was frozen for years after the Vioxx withdrawal.
Concentration is another error. Owning only one pharmaceutical stock exposes a portfolio to single-product risk. A diversified healthcare allocation should include at least two large-cap pharmas plus a medical device or managed care name.
Analyst outlook for Merck
Analysts at Goldman Sachs maintain a “Buy” rating on MRK with a price target of $120. They cite Keytruda’s label expansion and the subcutaneous formulation pipeline as key growth drivers. BMO Capital Markets assigns an “Outperform” rating with a $115 target, noting that Merck’s oncology pipeline is deeper than the market appreciates. UBS expects earnings per share to grow at a 9 percent compound annual rate through 2029, driven by Keytruda and the animal health business.
Bottom line for conservative investors
Merck offers pharmaceutical sector exposure with a yield that competes with utilities and REITs. The 3.1 percent dividend is well covered by earnings, the 13-year growth streak signals management commitment, and the Keytruda revenue base provides cash flow stability that is rare in drug development. For income investors, MRK is a core holding in the healthcare allocation.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
